Core Insights - Nutriband Inc. provided an update on key milestones and discussions from the Annual Shareholders Meeting held on January 24, 2026, in Orlando, Florida [1] Group 1: Leadership Changes - Two new directors were added to the board: Alessandro Puddu, an Italian Chartered Accountant with over 10 years of experience in audit and corporate advisory [2][3][5], and Viorica Carlig, a senior executive with over a decade of leadership experience in service-based companies and a Ph.D. in Economics [6] Group 2: Product Development - Nutriband is focusing on the development of its AVERSA™ FENTANYL product, with significant milestones including a strengthened collaboration with Kindeva for product development and a granted patent in Macao [9] - The company completed the commercial manufacturing process scale-up for AVERSA™ FENTANYL and issued a new US patent expanding its intellectual property protection [9] - A Type C meeting was held with the US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL [9] - Nutriband filed a new provisional patent application covering improved aversive formulations and initiated the development of a worldwide commercial brand name for AVERSA™ FENTANYL [9] Group 3: Financial Updates - The company is in the process of finalizing the sale of its Pocono subsidiary, with a nonrefundable penalty of $10,000 per week collected, totaling $30,000 so far [10] - A complaint was filed with FINRA regarding suspected naked short selling on behalf of shareholders [11] - The company reminded shareholders that warrants issued during its NASDAQ uplisting will expire on October 1, 2026, with 91,090 warrants set to expire at a strike price of $6.43, totaling $5,856,112 if exercised [12] Group 4: Technology Overview - Nutriband's AVERSA™ technology incorporates aversive agents into transdermal patches to prevent drug abuse and misuse, with a broad intellectual property portfolio covering multiple countries [13][14]

Core Insights - Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5 million to EarthVision Bio, with the transaction expected to close on December 31, 2025 [2][3] Company Overview - EarthVision Bio is developing sustainable products created by Dr. Gordon Moore, founder of Intel, and Dr. Hans Franke, former chairman of Chevron Europe, focusing on eco-friendly alternatives to plastic, molded fiber, wood, and paper products [3] - Nutriband Inc. will retain 10% of the shareholding in EarthVision Bio following the acquisition [2][3] Financial Implications - Proceeds from the sale of Pocono Pharma will be used by Nutriband Inc. to further develop its AVERSA Fentanyl product, which is projected to achieve annual U.S. sales between $80 million and $200 million [4] Product Development - Nutriband's AVERSA™ technology is designed to prevent the abuse, misuse, and accidental exposure of transdermal drugs, particularly opioids, and is protected by a broad intellectual property portfolio with patents granted in multiple countries [5][6]

Core Points - Nutriband Inc. has declared a 25% preferred stock dividend, with shareholders of record on July 25, 2025, receiving one preferred share for every four common shares held, payable on August 5, 2025 [1] - Each preferred share will be convertible to one common share following FDA approval of the AVERSA Fentanyl product, and if unconverted, will receive annual cash dividends from company profits as determined by the Board of Directors [2] - The CEO emphasized the company's focus on creating shareholder value and advancing the commercialization of the AVERSA Fentanyl product, highlighting recent progress in manufacturing scale-up with Kindeva [3] Product Information - AVERSA™ technology is designed to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly fentanyl, while ensuring accessibility for patients in need [4] - Nutriband is primarily focused on developing transdermal pharmaceutical products, with the AVERSA™ abuse-deterrent fentanyl patch as its lead product [5] Company Overview - Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products, with a strong emphasis on abuse-deterrent technologies [5]